INTRODUCTION: [(11)C] PBR28 binding to translocator protein (TSPO) was evaluated for imaging of acute and chronic inflammation using two established rat models. METHODS: Acute inflammation was induced by local carrageenan injection into the paw of Fisher 344 rats (model A). T-cell mediated adjuvant arthritis was induced by heat-inactivated Mycobacterium butyricum injection in Lewis rats (model B). Micro-PET scan was performed after injection of approximately 35 MBq [(11)C]PBR28. In model A, volumes of interest (VOIs) were defined in the paw of Fisher 344 rats (n=6) with contralateral sham treatment as control. For model B, VOIs were defined in the tail, sacroiliac joints, hips, knees and thigh muscles of M. butyricum treated animals (n=8) and compared with sham-treated controls (n=4). The peak (11)C-PBR28 SUV (SUVpeak) and area under the curve (AUCSUV) of 60-minute time-activity data were calculated. Immunohistochemistry for CD68, a macrophage stain, was performed from paw tissues. In addition, the [(11)C]PBR28 cell uptake was measured in lipopolysaccharide (LPS)-stimulated and non-stimulated macrophage cultures. RESULTS: LPS-stimulated macrophages displayed dose-dependent increased [(11)C]PBR28 uptake, which was blocked by non-labeled PBR28. In both models, radiotracer uptake of treated lesions increased rapidly within minutes and displayed overall accumulative kinetics. The SUVpeak and AUCSUV of carrageenan-treated paws was significantly increased compared to controls. Also, the [(11)C]PBR28 uptake ratio of carrageenan-treated vs. sham-treated paw correlated significantly with CD68 staining ratios of the same animals. In adjuvant arthritis, significantly increased [(11)C]PBR28 SUVpeak and AUCSUV values were identified at the tail, knees, and sacroiliac joints, while no significant differences were identified in the lumbar spine and hips. CONCLUSIONS: Based on our initial data, [(11)C]PBR28 PET appears to have potential for imaging of various inflammatory processes involving macrophage activation.
INTRODUCTION:[(11)C] PBR28 binding to translocator protein (TSPO) was evaluated for imaging of acute and chronic inflammation using two established rat models. METHODS: Acute inflammation was induced by local carrageenan injection into the paw of Fisher 344 rats (model A). T-cell mediated adjuvant arthritis was induced by heat-inactivated Mycobacterium butyricum injection in Lewis rats (model B). Micro-PET scan was performed after injection of approximately 35 MBq [(11)C]PBR28. In model A, volumes of interest (VOIs) were defined in the paw of Fisher 344 rats (n=6) with contralateral sham treatment as control. For model B, VOIs were defined in the tail, sacroiliac joints, hips, knees and thigh muscles of M. butyricum treated animals (n=8) and compared with sham-treated controls (n=4). The peak (11)C-PBR28 SUV (SUVpeak) and area under the curve (AUCSUV) of 60-minute time-activity data were calculated. Immunohistochemistry for CD68, a macrophage stain, was performed from paw tissues. In addition, the [(11)C]PBR28 cell uptake was measured in lipopolysaccharide (LPS)-stimulated and non-stimulated macrophage cultures. RESULTS:LPS-stimulated macrophages displayed dose-dependent increased [(11)C]PBR28 uptake, which was blocked by non-labeled PBR28. In both models, radiotracer uptake of treated lesions increased rapidly within minutes and displayed overall accumulative kinetics. The SUVpeak and AUCSUV of carrageenan-treated paws was significantly increased compared to controls. Also, the [(11)C]PBR28 uptake ratio of carrageenan-treated vs. sham-treated paw correlated significantly with CD68 staining ratios of the same animals. In adjuvant arthritis, significantly increased [(11)C]PBR28 SUVpeak and AUCSUV values were identified at the tail, knees, and sacroiliac joints, while no significant differences were identified in the lumbar spine and hips. CONCLUSIONS: Based on our initial data, [(11)C]PBR28 PET appears to have potential for imaging of various inflammatory processes involving macrophage activation.
Authors: Oliver Gaemperli; Joseph Shalhoub; David R J Owen; Frederic Lamare; Saga Johansson; Naghmeh Fouladi; Alun H Davies; Ornella E Rimoldi; Paolo G Camici Journal: Eur Heart J Date: 2011-09-19 Impact factor: 29.983
Authors: Rainer Rupprecht; Vassilios Papadopoulos; Gerhard Rammes; Thomas C Baghai; Jinjiang Fan; Nagaraju Akula; Ghislaine Groyer; David Adams; Michael Schumacher Journal: Nat Rev Drug Discov Date: 2010-12 Impact factor: 84.694
Authors: Anne Roivainen; Riitta Parkkola; Timo Yli-Kerttula; Pertti Lehikoinen; Tapio Viljanen; Timo Möttönen; Pirjo Nuutila; Heikki Minn Journal: Arthritis Rheum Date: 2003-11
Authors: Winnie Wai-Ying Kam; Steven R Meikle; Hong Zhou; Yu Zheng; Julie M Blair; Marcus Seibel; Colin R Dunstan; Richard B Banati Journal: PLoS One Date: 2012-01-25 Impact factor: 3.240
Authors: Marco L Loggia; Daniel B Chonde; Oluwaseun Akeju; Grae Arabasz; Ciprian Catana; Robert R Edwards; Elena Hill; Shirley Hsu; David Izquierdo-Garcia; Ru-Rong Ji; Misha Riley; Ajay D Wasan; Nicole R Zürcher; Daniel S Albrecht; Mark G Vangel; Bruce R Rosen; Vitaly Napadow; Jacob M Hooker Journal: Brain Date: 2015-01-12 Impact factor: 13.501
Authors: Catherine A Foss; Djahida Bedja; Ronnie C Mease; Haofan Wang; David A Kass; Subroto Chatterjee; Martin G Pomper Journal: Biochem Biophys Res Commun Date: 2015-04-06 Impact factor: 3.575
Authors: Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler Journal: Nat Rev Clin Oncol Date: 2019-06-26 Impact factor: 66.675
Authors: Sean J English; Jose A Diaz; Xia Shao; David Gordon; Melissa Bevard; Gang Su; Peter K Henke; Virginia E Rogers; Gilbert R Upchurch; Morand Piert Journal: EJNMMI Res Date: 2014-05-10 Impact factor: 3.138
Authors: Léonard de Vinci Kanda Kupa; Carine C Drewes; Eric D Barioni; Camila L Neves; Sandra Coccuzzo Sampaio; Sandra H P Farsky Journal: Front Pharmacol Date: 2017-10-27 Impact factor: 5.810
Authors: Benjamin L Franc; Sam Goth; John MacKenzie; Xiaojuan Li; Joseph Blecha; Tina Lam; Salma Jivan; Randall A Hawkins; Henry VanBrocklin Journal: Mol Imaging Date: 2017-01-01 Impact factor: 4.488